公开(公告)号：US20090099155A1

公开(公告)日：2009-04-16

申请号：US10598302

申请日：2005-09-09

申请人： John Gordon Allen ,  Karin Briner ,  Michael Philip Cohen ,  Christopher Stanley Galka ,  Sarah Lynne Hellman ,  Maria Angeles Martinez-Grau ,  Matthew Robert Reinhard ,  Michael John Rodriguez ,  Roger Ryan Rothaar ,  Michael Wade Tidwell ,  Frantz Victor ,  Andrew Caerwyn Williams ,  Deyi Zhang ,  Steven Armen Boyd ,  Richard Gerard Conway ,  Arundhati S. Deo ,  Wai-Man Lee ,  Christopher Stephen Siedem ,  Ajay Singh ,  Michael Philip Mazanetz

发明人： John Gordon Allen ,  Karin Briner ,  Michael Philip Cohen ,  Christopher Stanley Galka ,  Sarah Lynne Hellman ,  Maria Angeles Martinez-Grau ,  Matthew Robert Reinhard ,  Michael John Rodriguez ,  Roger Ryan Rothaar ,  Michael Wade Tidwell ,  Frantz Victor ,  Andrew Caerwyn Williams ,  Deyi Zhang ,  Steven Armen Boyd ,  Richard Gerard Conway ,  Arundhati S. Deo ,  Wai-Man Lee ,  Christopher Stephen Siedem ,  Ajay Singh ,  Michael Philip Mazanetz

IPC分类号： A61K31/55 ,  C07D223/16 ,  C07D417/12 ,  C07D401/12 ,  A61P3/04 ,  A61P25/22 ,  C07D409/12 ,  C07D403/12 ,  C07D405/12

CPC分类号： C07D223/16 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12

摘要： The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is -C≡C-R10, -O-R12, -S-R14, or -NR24R25; and other substituents are as defined in the specification.

摘要翻译： 本发明提供式I的6-取代2,3,4,5-四氢-1H-苯并吖庚因作为选择性5-HT 2C受体激动剂用于治疗5-HT2C相关疾病，包括肥胖，强迫症/强迫症，抑郁症和 焦虑：其中：R6为-C≡C-R10，-O-R12，-S-R14或-NR24R25; 和其它取代基如说明书中所定义。

公开(公告)号：US20120028961A1

公开(公告)日：2012-02-02

申请号：US13192707

申请日：2011-07-28

申请人： JOHN GORDON ALLEN ,  Karin Briner ,  Michael Philip Cohen ,  Christopher Stanley Galka ,  Sarah Lynne Hellman ,  Maria Angeles Martinez-Grau ,  Matthew Robert Reinhard ,  Michael John Rodriguez ,  Roger Ryan Rothhaar ,  Michael Wade Tidwell ,  Frantz Victor ,  Andrew Caerwyn Williams ,  Deyi Zhang ,  Steven Armen Boyd ,  Richard Gerard Conway ,  Arundhati S. Deo ,  Wai-Man Lee ,  Christopher Stephen Siedem ,  Ajay Singh ,  Michael Philip MAZANETZ

发明人： JOHN GORDON ALLEN ,  Karin Briner ,  Michael Philip Cohen ,  Christopher Stanley Galka ,  Sarah Lynne Hellman ,  Maria Angeles Martinez-Grau ,  Matthew Robert Reinhard ,  Michael John Rodriguez ,  Roger Ryan Rothhaar ,  Michael Wade Tidwell ,  Frantz Victor ,  Andrew Caerwyn Williams ,  Deyi Zhang ,  Steven Armen Boyd ,  Richard Gerard Conway ,  Arundhati S. Deo ,  Wai-Man Lee ,  Christopher Stephen Siedem ,  Ajay Singh ,  Michael Philip MAZANETZ

IPC分类号： A61K31/55 ,  A61P25/22 ,  A61P25/00 ,  A61P25/24 ,  C07D223/16 ,  A61P3/04

CPC分类号： C07D223/16 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12

摘要： The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.

摘要翻译： 本发明提供式I的6-取代2,3,4,5-四氢-1H-苯并[d]吖庚因作为选择性5-HT 2C受体激动剂，用于治疗5-HT 2C相关病症，包括肥胖，强迫症/强迫症 ，抑郁症和焦虑症：其中：R6为-S-R14; 和其它取代基如说明书中所定义。

公开(公告)号：US08580780B2

公开(公告)日：2013-11-12

申请号：US13192707

申请日：2011-07-28

申请人： John Gordon Allen ,  Karin Briner ,  Christopher Stanley Galka ,  Maria Angeles Martinez-Grau ,  Matthew Robert Reinhard ,  Michael John Rodriguez ,  Roger Ryan Rothhaar ,  Michael Wade Tidwell ,  Frantz Victor ,  Deyi Zhang ,  Steven Armen Boyd ,  Arundhati S. Deo ,  Wai-Man Lee ,  Christopher Stephen Siedem ,  Ajay Singh

发明人： John Gordon Allen ,  Karin Briner ,  Christopher Stanley Galka ,  Maria Angeles Martinez-Grau ,  Matthew Robert Reinhard ,  Michael John Rodriguez ,  Roger Ryan Rothhaar ,  Michael Wade Tidwell ,  Frantz Victor ,  Deyi Zhang ,  Steven Armen Boyd ,  Arundhati S. Deo ,  Wai-Man Lee ,  Christopher Stephen Siedem ,  Ajay Singh

IPC分类号： A61P3/04 ,  A61P25/22 ,  A61P25/24 ,  A61P25/30 ,  A61K31/55 ,  C07D223/16 ,  C07D401/12 ,  C07D417/12 ,  C07D413/12 ,  C07D403/12 ,  C07D409/12 ,  C07D405/12 ,  C07D413/14 ,  C07D417/06 ,  C07D403/06

CPC分类号： C07D223/16 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12

摘要： The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.

摘要翻译： 本发明提供式I的6-取代2,3,4,5-四氢-1H-苯并[d]吖庚因作为选择性5-HT 2C受体激动剂，用于治疗5-HT 2C相关病症，包括肥胖，强迫症/强迫症 ，抑郁症和焦虑症：其中：R6为-S-R14; 和其它取代基如说明书中所定义。